...
Authors
Clear selection
...
Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study

Journal of Hypertension 42(10):p 1720-1727, October 2024. 

DOI: 10.1097/HJH.0000000000003789

Conflicts of interests: F.G. is supported by German Foundation for Heart Research (Deutsche Herzstiftung) and has received speaker honoraria from AstraZeneca. L.L. has received speaker honoraria from ReCor Medical and Medtronic. M.B. is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; SFB TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cytokinetic, Edwards, Medtronic, Novartis, ReCor Medical, Servier and Vifor. U.L. has received speaker honoraria from Amgen, BMS, Daiichi Sankyo, Novartis and Sanofi, all outside the submitted work. F.M. is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung. His institution (Saarland University) has received scientific support from Ablative Solutions, Medtronic and ReCor Medical. He has received speaker honoraria/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. M.S. has received speaker honoraria from AstraZeneca, BMS, Daiichi Sankyo, Novartis, Pfizer and Sanofi and consulting fees from CSL Vifor, MSD and TAD, all outside the submitted work. The other authors do not have conflicts of interest.